‘it’s all about checkpoint inhibitors’ – rob jones on bladder cancer during asco 2017
Published 7 years ago • 349 plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
2:01
immune checkpoint inhibitors in urothelial bladder cancer
-
2:01
using checkpoint inhibitors at earlier stages of bladder cancer – the next step in immunotherapy?
-
1:28
immune checkpoint inhibitors and sitravatinib in bladder cancer
-
1:27
highlights in kidney and bladder cancer at asco 2023
-
1:36
the synergistic antitumor activity of pan-pi3k inhibition and ici's in bladder cancer
-
8:11
bladder cancer highlights from asco gu 2017: clinical implications
-
4:45
highlights in kidney and bladder cancer at asco gu 2021
-
3:31
the use of immunotherapy as a first-line therapy for bladder cancer
-
32:19
asco updates 2020: bladder cancer with dr. manoj bupathi
-
1:14
how can we continue the success of checkpoint inhibitors for bladder cancer treatment?
-
3:51
is pembrolizumab alone sufficient to treat bladder cancer?
-
4:11
what's next for checkpoint inhibitors in metastatic urothelial bladder cancer?
-
1:29
will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
-
1:56
immune checkpoint inhibitors for urothelial carcinoma: the current landscape
-
6:00
use of immune checkpoint inhibitors for bladder cancer
-
2:41
should pd-l1 be used as a biomarker for immunotherapy in bladder cancer?
-
1:06
dr. o'donnell compares checkpoint inhibitors in bladder cancer
-
2:53
effect of fgfr status on checkpoint inhibitor response in bladder cancer
-
1:06
combining tkis with checkpoint inhibitors for prostate cancer – is this the way forward?